U.S. Markets close in 2 hrs 12 mins

Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • VERV
  • Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101.

  • VERVE-101 is a potential single-course gene-editing treatment for atherosclerotic cardiovascular disease (ASCVD).

  • The data will be presented today at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference.

  • VERVE-101 is being developed initially for heterozygous familial hypercholesterolemia (HeFH), a potentially fatal genetic heart disease.

  • VERVE-101 is designed to inactivate the PCSK9 gene, resulting in a sustained reduction in PCSK9 protein levels and increased LDLR expression, leading to lower LDL-C levels and reduced risk for ASCVD.

  • 70% mean editing at the PCSK9 target site in NHPs treated with 1.5 mg/kg VERVE-101 (n=22) as observed in liver biopsies at two weeks.

  • Significant, durable reductions in PCSK9 and LDL-C levels were seen after a single dose at two different dose levels when measured at day 14 and day 180.

  • Sustained editing of PCSK9 in regenerated liver lobes at 95 days post-treatment was observed.

  • No significant off-target editing was observed in human liver cells.

  • A generally well-tolerated profile with VERVE-101 at all doses was seen, but mild transient elevated liver enzymes and no impact on glucose levels were observed.

  • The Company plans to submit IND for human trials in 2022.

  • Price Action: VERV stock is up 0.81% at $47.40 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.